Ibex Wealth Advisors Alaunos Therapeutics, Inc. Transaction History

Ibex Wealth Advisors

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 12, 2019	SELL	$4.13 - $6.94 $10,325 - $17,350	-2,500 Closed	0 $0
Q2 2019 Jul 30, 2019	BUY	$3.98 - $6.2 $9,950 - $15,500	2,500 New	2,500 $14,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Ibex Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Ibex Wealth Advisors with notifications on news.